Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Recombinant IL-7 for T-Cell Recovery Post-Transplant
NCT03941769Phase 2Completed
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Sep 2020
- Primary completion
- Mar 2023
- Modality
- Cytokines & Interferons
- Countries
- 1
01
Overview
A Phase 2 trial of recombinant human interleukin-7 in acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), chronic myeloid leukemia (CML), Myeloproliferative Neoplasm (MPN), myelofibrosis (MF), sponsored by University of Texas MD Anderson Cancer Center. Started Sep 2020; status: completed.
02
Drugs
recombinant human interleukin-7
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)chronic myeloid leukemia (CML)Myeloproliferative Neoplasm (MPN)myelofibrosis (MF)
Beyond the preview
Go deeper on NCT03941769.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03941769.